Biocon Limited has informed the Exchange about the Certificate pursuant to SEBI Master Circular no. SEBI/HO/DDHS/PoD1/P/CIR/2024/54dated May 22, 2024.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited has submitted a quarterly compliance certificate to the stock exchanges regarding its Commercial Paper (CP) issuances, as required by SEBI's master circular for non-convertible securities. The total CP issuance during calendar year 2025 up to June 30, 2025 stood at Rs. 1,170 crores. The company confirms that CP proceeds were used only for the disclosed purposes and all listing conditions were adhered to. Two specific CPs are detailed: one of Rs. 570 crores (issued January 2025, matured April 2025) used for acquiring equity in a subsidiary, and another of Rs. 600 crores (issued April 2025, maturing September 2025) used for refinancing existing borrowings. The company also confirmed its bank facilities continue to be classified as 'Standard', and there has been no material adverse change in its financial status affecting CP credit ratings.
This is a routine regulatory compliance filing and not directly price-moving, but it reveals that Biocon has raised Rs. 1,170 crore via short-term Commercial Papers in 2025, partly to fund a subsidiary acquisition and partly to refinance existing debt. Stable 'Standard' asset classification and unchanged credit outlook suggest continued debt servicing ability.